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 Abstract:  In the recent years, the  “ tumor microenviron-
ment ” has been receiving growing attention due to its 
involvement in neoplastic transformation, tumor growth, 
invasion, and protection of tumor cells from host immune 
response. All these events are facilitated by chemical sig-
nals produced by the tumor as well as the surrounding 
stromal cells. This review is divided into two main parts in 
which the first part discusses the receptor tyrosine kinase 
(RTK)-mediated growth factor signaling, steroid hormone 
(SH) signaling, ancient signaling pathways, and other 
molecules that are involved in tumorigenesis and how 
they interact with each other to create a complex tumor 
microenvironment. In the second part, we bring together 
the recent nanocarrier-mediated drug delivery approaches 
to target the signaling pathways/molecules present in the 
tumor microenvironment. 
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1   Introduction 
 Cancer can be considered as a developmental disorder 
because most of the signaling pathways responsible for 
tumor formation are the ones involved in embryo devel-
opment. This is evident by the resemblance of aggressive 
tumor cells with embryonic stem cells by means of their 
plastic, multipotent nature. Deregulation/dysfunction of 
developmental pathways in and around tumor cells as 
well as the absence of many regulatory checkpoints results 
in aberrant uncontrolled growth of tumor cells. Research 
over years has contributed substantially to our under-
standing of the cellular and molecular interactions that 
occur in the tumor microenvironment that orchestrates 
tumorigenesis. The constantly evolving tumor microenvi-
ronment is rich in growth factors, which elicit a cascade 
of signaling events through specific cell-surface receptors, 
leading to rapid proliferation, angiogenesis, and resist-
ance to cell death, and endure epithelial-mesenchymal 
transition and metastasis. Our knowledge about the role 
of tumor microenvironment in cancer has improved sig-
nificantly, moving from a conceptual framework toward 
the development of novel strategies to treat cancer. Com-
bining therapies that target not only the tumor cells but 
also the tumor microenvironment and/or the signaling 
pathways providing resistance to the cancer cells from 
responding to chemotherapy have greater degree of 
success in cancer treatment  [1] . Nanoparticles designed 
based on the characteristics and specific signaling inter-
action of the tumor microenvironment is a promising 
strategy to combat cancer. For instance, nanoparticles 
sensitive to the acidic pH of the tumor microenvironment 
provides selectivity to tumor cells over the normal ones, 
thus enhances specificity and drug delivery efficiency  [2, 
3] . The first part of this review presents a holistic discus-
sion about the important signaling molecules/pathways 
such as the receptor tyrosine kinases (RTK), steroid hor-
mones (SHs), and the ancient signaling pathways that are 
altered during cancer and signaling interactions enriching 
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the tumor microenvironment. Interested readers are also 
referred to other in-depth reviews on specific topics under 
most of the sections. The second part consolidates how 
the signaling molecules discussed in the previous part are 
exploited to functionalize nanoparticle-mediated thera-
peutic strategies to treat cancer effectively. 
2   Receptor tyrosine kinase (RTK) 
signaling 
 Signaling via mutated or constitutively active variant of 
RTK function as a potential means for cancer cells to evade 
host mechanisms and develop tumors. A huge deal of 
attention has been diverted toward RTK signaling because 
of their overexpression commonly found in many cancers, 
their ability to crosstalk between themselves, and impor-
tantly, they connect the extracellular cues with intracellu-
lar effector pathways. As a result, RTK receptor expression 
has been extensively used as a prognostic biomarker in 
many malignancies. There are several RTKs, and only the 
primary ones upregulated in cancer are reviewed here. 
2.1   ErbB family of receptors 
 The epidermal growth factor receptor (EGFR) is a member 
of the ErbB family, a subfamily comprised of ErbB1/HER1/
EGFR, ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4. 
The ErbB receptors are prominent cancer drivers, which 
form active homo- or heterodimers upon ligand binding 
 [4] . ErbB receptors bind to EGF produced by the same 
cell (autocrine) or other cells (paracrine). After ligand 
binding, the dimerized receptor ’ s intracellular tyrosine 
kinase domain will be activated causing phosphorylation 
of specific tyrosine residues that serve as docking sites for 
proteins containing Src homology 2 (SH2) domains such as 
Grb2, Shc1, p85, PLC γ , and JAK1, leading to the activation 
of several intracellular signaling pathways. These down-
stream signaling cascades include the Ras/MAPK/extra-
cellular signal-regulated kinase (ERK), PI3K/Akt, JAK/ 
STAT, and PLC γ /protein kinase-C (PKC) pathways for cell 
proliferation, survival, and mobility  [5, 6] . The intracel-
lular kinase domain of HER3 is thought to be an inactive 
pseudokinase that lacks several catalytically important 
residues and so it primarily signals by heterodimerizing 
with HER2  [7] . However, it was reported to have sufficient 
kinase activity to trans-autophosphorylate its intracellu-
lar region  [8] . Recently, HER3 overexpression in various 
tumors including colorectal, gastric, breast, and ovarian 
cancers of HER3 has been associated with worse survival, 
and its effect on overall survival was significantly higher 
when HER2 was co-overexpressed  [9] . ErbB receptors are 
expressed at high levels in various types of cancer, and the 
levels of gene/protein expression is usually correlated with 
the growth, state, and aggressiveness of different cancers 
 [10, 11] . For instance, HER2 amplification occurs in 20% of 
breast cancers  [11] , and 54% of glioblastoma exhibit EGFR 
overexpression  [12] . Glioblastoma cells often present both 
the wild-type EGFR gene amplification and the constitu-
tively active variant EGFRvIII, resulting in increased EGFR 
signaling  [12] . However, EGFRvIII expression without 
EGFR gene amplification is fairly uncommon, suggest-
ing that EGFR gene amplification may precede EGFRvIII 
mutation  [13] . All the aforementioned features make ErbB 
receptors a potential therapeutic target to treat tumors. A 
detailed review on targeting ErbB receptors can be found 
in  [14] . 
2.2   Fibroblast growth factor receptor 
(FGFR) family 
 Fibroblast growth factor receptors (FGFRs) are transmem-
brane tyrosine-kinase receptors that coordinate a variety 
of cellular functions. There are 4 FGFRs (FGFR1-4) and 22 
FGF ligands  [15] . Binding of FGFRs to FGF ligands activate 
several downstream signaling pathways, including Ras/
MAPK/ERK, PLC γ /PKC, PI3K/Akt, and JAK/STAT. Being 
a crucial signaling for basic processes such as prolifera-
tion, survival, angiogenesis, and migration, deregulated 
FGF signaling can contribute to the development and 
progression of tumors  [16] . FGFR signaling is altered in 
many cancers including benign skin tumors  [17] , prostate 
 [18] , bladder, and breast cancers  [19 – 21] . Breast cancer 
cells have been reported to overexpress FGFR1, 2, 4 and 
display mutations in FGFR2 and 4  [21] . Moreover, emerg-
ing data suggest that in addition to the known functions 
of FGF signaling in promoting tumor cell proliferation and 
survival, FGF signaling might also regulate epithelial-to-
mesenchymal transmission (EMT)  [22] tumor metastasis 
and lymphangiogenesis in a vascular endothelial growth 
factor-C (VEGF-C)-dependent mechanism  [23] . Overex-
pression of FGFR1 and its altered splicing mechanisms, 
leading to increased expression of FGFR1 β isoform has 
been associated with high-grade/stage bladder cancer  [24, 
25] . Although, activating mutation and overexpression of 
FGFR3 is a common phenomenon observed in low-grade 
bladder cancer  [19] , a switch from its epithelial to mes-
enchymal isoform with wider ligand affinity is thought 
to have more deleterious effects  [19, 26] . Particularly, 
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FGFR1 has been considered as a potential oncogene in 
breast cancer because its deregulated signaling contrib-
utes to cell proliferation, growth, angiogenesis, EMT, and 
cell migration in S115 breast cancer  [20] . Overall, FGFRs 
stands as an attractive target for therapeutic intervention 
in cancer  [19, 21, 27] . 
2.3   Insulin and insulin-like growth factor 
receptor (IGFR) family 
 The insulin receptor (IR-A and IR-B) and the insulin-like 
growth factor receptor (IGF1R and IGF2R) are tyrosine 
kinase membrane-bound receptors that share  ∼ 60% 
sequence homology and regulates glucose homeostasis 
and growth in response to nutrient availability in cells. 
IR has two isoforms, IR-A and IR-B, which are predomi-
nantly expressed in the fetal and adult tissues, respec-
tively. However, cancer cells preferably overexpress the 
fetal isoform IR-A, which has the advantages of generat-
ing hybrid receptors with IGFIR and to have equal affinity 
to IGF1/IGF2 like that of IGF1R  [28 – 30] . In fact, the hybrid 
receptors are reported to possess higher affinity for IGF1 
than insulin and function predominantly as an IGF1 recep-
tor  [31] . IR-mediated nonmetabolic insulin signaling has 
been found in human myosarcoma cells  [32] , colon cancer 
cells  [33] , breast, prostate, and colorectal cancers  [34 – 36] . 
Moreover, IR-associated obesity, -type 2 diabetes mellitus 
(T2DM) and -hyperinsulinemia are some important risk 
factors for several malignancies including breast cancer 
 [37] . Upon insulin binding to IR, the activated RTK will 
phosphorylate insulin receptor substrate proteins (IRS1-4), 
providing docking sites for effectors/adapter proteins, con-
taining SH2 domains. This triggers a cascade of reactions 
causing the activation of PI3K/Akt and Ras/MAPK path-
ways that mediate the metabolic and mitogenic activities 
of insulin, respectively  [38, 39] . The antiapoptotic activ-
ity of insulin is reported to involve both the PI3K/Akt and 
MAPK pathways  [40, 41] . Insulin also possesses angiogenic 
properties in a VEGF-dependent or -independent manner 
through PI3K/Akt and MAPK pathways  [42, 43] . While the 
ability of insulin to stimulate PI3K is lost in the presence 
of insulin resistance and hyperinsulinemia, its capacity to 
activate MAPK pathway is enhanced  [39] . Thus, hyperinsu-
linemia-mediated increased levels of circulating insulin in 
association with IR-A overexpression in cancer cells may 
cause abnormal nonmetabolic effects of IR, such as cell 
survival, proliferation, migration, and angiogenesis, the 
key events that occur during tumor growth and metastasis 
 [38, 43] , making the circulating insulin a risk factor of colo-
rectal, pancreatic, and breast cancers  [44, 45] . 
 IGF1R is a potential cellular oncogene through which 
both IGF1 and IGF2 exert their mitogenic, antiapoptotic, 
and transforming activities  [46] . IGF1R expression is seen 
as a prerequisite for tumor formation because mouse 
fibroblasts deprived of IGF1R were unable to be trans-
formed by a number of oncogenes  [47, 48] . IGF1R signal-
ing plays critical steps, namely, cell adhesion, migration, 
invasion, and angiogenesis during the metastatic cascade 
and is involved in a wide range of cancers including the 
breast, prostate, pediatric, cervix, and ovarian cancers 
 [37] . Ligand binding to the extracellular subunit of IGF1R 
causes autophosphorylation and conformational changes 
of its tyrosine kinase domain, leading to the binding of 
IRS1-4 and Shc proteins. Phosphorylation of these pro-
teins eventually activates at least two signaling pathways: 
PI3K/Akt and Ras/Raf/MEK/ERK. The antiapoptotic effect 
of IGF1R is mainly exerted by the PI3K/Akt pathway acti-
vation. Phosphorylated IRS activates PI3K, which helps 
the conversion of phosphatidylinositol-4,5-bisphosphate 
(PIP2) to PIP3, the reaction inhibited by phosphatase 
and tensin homolog (PTEN). PIP3 phosphorylates Akt as 
well as PKC proteins, both of which regulate the meta-
bolic activities of the cell such as glucose uptake  [49, 50] . 
Importantly, activated Akt interferes with the antiapop-
totic and proapoptotic functions of several proteins. Upon 
phosphorylation by Akt, Bcl-2-associated death promoter 
(BAD) becomes inactivated and allows the antiapoptotic 
activity of Bcl-2, promoting cell survival. In addition, 
phosphorylated-Akt also inhibits the proapoptotic protein 
caspase-9 and prevents cell death  [51] . By activating 
nuclear factor- κ B- (NF- κ B), Akt can also regulate the 
expression of antiapoptotic genes  [52] . On the other hand, 
phosphorylated Shc protein binds to Grb2 that recruits 
Son of Sevenless (SOS), which in turn activates Ras/Raf/
MER/ERK pathway. Activated ERK get translocated to the 
nucleus and regulates target gene expression, influencing 
cell proliferation and survival  [53] . 
 IGF1 and IGF2 are single-chain polypeptides that 
share 62% sequence homology and generate multiple 
transcripts depending on their transcription initiation 
promoter sites and alternative splicing mechanisms. The 
availability of free IGF1 to interact with IGF1R is regulated 
by the levels of the six IGF-binding proteins (IGFBP1-6). 
Under normal physiological conditions, only 1% of the 
IGFs circulate free, while others are bound to the IGFBPs 
 [54] . IGFBPs and their associated proteases are important 
in IGFR signaling because they hydrolyzes IGFBPs, causing 
the release of bound IGFs, enabling them to interact with 
IGF1R. Diet, nutrition, and growth hormones have an 
influence on IGF1 expression  [55] . Similarly, IGF1R expres-
sion is also affected by nutrition, growth factors, and 
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SHs  [56] . Although other growth factors stimulate IGF1R 
production, IGF1 functions as its negative regulator  [57] . 
Hyperinsulinemia can also favor the production of IGF1 
and increases its bioavailability and IGF1R signaling by 
modulating IGFBPs  [58] . Both IGF1 and IGF2 are overex-
pressed in an array of cancers such as the colon, prostate, 
breast, colorectal, thyroid, lung, pancreatic cancers, and 
several sarcomas  [59, 60] . Insulin and IGF1 have the ability 
to cross-bind to each other ’ s receptor, although with much 
less affinity than that of their preferred ligand  [61] . Unlike 
IGF1R, IGF2R has no tyrosine kinase activity, and it binds 
to IGF2 and reduces its bioavailability by sending it for 
lysosomal degradation  [62] . Because of this effect, IGF2R 
has been considered as a potential tumor-suppressor mol-
ecule. In-depth reviews on IR, IGF, and IGF1R in cancer 
can be found elsewhere  [37, 39, 63, 64] . 
2.4   Platelet-derived growth factor receptor 
(PDGFR) 
 There are two types of the platelet-derived growth factor 
receptors: PDGFR α and PDGFR β that are activated by five 
different disulfide-linked dimer ligands: PDGF-AA, -BB, -AB, 
-CC, and -DD with varying specificity. Although all PDGFs 
except the PDGF-DD interact with PDGFR α and induce 
receptor dimer formation, PDGF-AA is the most potent 
ligand of PDGFR α . PDGF-BB and PDGF-DD interacts with 
PDGFR β  [65] . Ligand-binding to receptors induces homo- 
or heteroreceptor dimerization, leading to the activation 
of their intrinsic tyrosine kinase domain and subsequent 
recruitment of SH2-domain-containing signaling proteins, 
which activates the downstream pathways that cause the 
basic cellular processes like, proliferation, migration, and 
transformation  [66] . PDGFs (-BB and -DD) and the receptors 
(PDGFR α and PDGFR β ) are overexpressed in many tumors 
including the breast  [67] , prostate  [68] , kidney  [69] , lung 
 [70] , ovarian  [71] , glioma  [72] , melanoma  [73] , and bone 
 [74] . Expression of PDGFs and PDGFRs are found even in 
low-grade gliomas, unlike the EGFR expression found only 
in high-grade tumors, suggesting an early role for PDGF 
signaling in gliomas  [75] . PDGFR signaling in tumor is pri-
marily associated with angiogenesis and metastasis like 
in the case of gliomas and breast cancer  [67, 76] . PDGF-B, 
-C, and -D has been reported to enhance tumor angiogen-
esis through enhanced vascular endothelial growth factor 
(VEGF) expression  [77 – 79] . Tumor cell-secreted PDGF-B 
also functions to determine the fate of the mesenchymal 
stem cells  in vitro through a transmembrane glycoprotein 
receptor, neuropilin-1 (NRP-1) signaling  [80] , and it should 
be noted that NRP-1 expression is positively correlated with 
the invasion ability of cancer cells. Recently, it was dem-
onstrated that the knockdown of PDGFR β in glioblastoma 
stem cells downregulates the critical angiogenesis regula-
tor VEGF  [81] . In this context, VEGF165 has been reported 
to bind to NRP-1 and trigger the NRP-1/VEGFR2/PI3K/Akt 
signaling pathway causing tumor angiogenesis, cancer cell 
invasion, and tumorigenesis  [82] . PDGFR also influence 
the cancer microenvironment by recruiting nearby stromal 
cells, which facilitate tumor-stromal cell interaction that 
determines tumor development  [83, 84] . The role of PDGFR 
in cancer has been critically reviewed before  [85] . 
2.5   Vascular endothelial growth factor 
receptors (VEGFR) 
 The vascular endothelial growth factor (VEGF) family is 
crucial for angiogenesis, lymphangiogenesis, and vascu-
logenesis, and it consists of six members: VEGF (or VEGF-
A), VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental 
growth factor (PlGF). The biological effects of VEGF are 
mediated by their interaction with the three protein-tyros-
ine kinase vascular endothelial growth factor receptors 
(VEGFR1, VEGFR2, and VEGFR3). The two non-enzymatic 
receptors, NRP-1 and NRP-2, are proposed to facilitate 
the binding of various VEGF ligands to their primary 
receptors  [86] . During tumorogenesis, it is vital that the 
rapidly proliferating tumor grown beyond 1 – 2 mm receive 
adequate blood supply through newly generated tumor 
blood vessels. VEGFs overproduced by tumor cells are 
essential to drive angiogenesis that enables tumor growth 
and metastasis  [87] . Binding of VEGFs to their appropri-
ate VEGFR induces receptor dimerization that leads to 
autophosphorylation of the receptor ’ s intrinsic tyrosine 
residues within the kinase domain-stimulating catalytic 
activity. This will ultimately activate the intracellular Ras/
Raf/MEK, PLC γ , and PI3K/Akt pathways resulting in the 
survival of immature endothelial cells, growth and migra-
tion of vascular endothelial cells, and enhanced capillary 
vascular permeability through different mechanisms 
 [88] . VEGF signaling through the PI3K/Akt pathway is 
also known to regulate the expression of metastasis- and 
fibrosis-related genes belonging to the TGF- β and con-
nective tissue growth factor family  [89, 90] . Endothelial 
isoform of nitric oxide synthase (eNOS), the major source 
of nitric oxide (NO) can also be stimulated by VEGFR 
signaling downstream of Akt activation to increase 
vascular permeability  [91, 92] . VEGFs and VEGFRs are 
overexpressed in various human primary solid tumors 
including the ovarian, breast, non-small-cell lung carci-
nomas, colon, and colorectal cancers. Although VEGFR 
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is primarily expressed in tumor vessels and associated 
with tumor-angiogenesis  [93] , they are also expressed in 
tumor cells  [93] , enabling tumor growth  [94] . 
 VEGF-A exerts its activity by binding to VEGFR1 and 
VEGFR2. VEGFR1 expressed in the endothelial cells pri-
marily functions during development and tumor angio-
genesis by binding to VEGF-A, -B, and PIGF  [101, 102] , 
and it is overexpressed in tumor cells  [103] . Although 
the expression level of the VEGFR1-specific ligand, PIGF, 
is increased in many tumors  [104] , the function of this 
protein in tumor development is controversial because 
it has been associated with both tumor suppression 
 [105, 106] as well as enhanced tumor growth  [107, 108] . 
Similarly,  plgf knockout also displayed tumor inhibi-
tion only in some cases but not always  [109] . However, 
recently, PIGF was shown to be involved in tumor cell 
growth through autocrine/paracrine VEGFR1 signaling. 
Although, VEGFR2 has lower affinity for VEGF-A than 
VEGFR1, VEGFR2 exhibits stronger tyrosine kinase activ-
ity in response to its ligands, which makes VEGFR2 the 
major receptor of VEGF-A  [110] , and it can function both in 
an autocrine and paracrine fashion  [94] . VEGFR3 expres-
sion in the vascular endothelium begins with the purpose 
of remodeling the primary capillary plexus during embry-
onic development. But, along development and in adult 
life, VEGFR3 expression gets restricted to the lymphatic 
endothelial cells and mainly contributes to lymphangi-
ogenesis  [111] . VEGFR3 exerts its signaling by binding to 
VEGF-C and -D, which are overexpressed in tumors  [112] . 
Signaling through VEGF/VEGFR3 in lymphatic vessels 
is worth investing because the lymphatic vasculature 
is a route for tumor metastasis. Recently, Karnezis et al. 
 [113] have shown that the collecting lymphatics serve as 
an important place for cancer metastasis by linking the 
signals via the VEGF-D/VEGFR2/VEGFR3 and the prosta-
glandin pathways. Contrary to its role in tumorigenesis, a 
soluble form of VEGFR2 (splice variant) was found as an 
inhibitor of lymphangiogenesis by sequestering VEGF-C 
and preventing it from activating VEGFR3  [114] . To have 
a deeper understanding of VEGF signaling in tumor, the 
readers can refer to Rastogi (2008)  [88] . 
3   Steroid hormones 
 SHs that are associated with cancer are the ones that can 
elicit cell proliferation and enable cancer progression. 
Deregulated estrogen and androgen (also progesterone) 
signaling is the predominant causative agent of breast, 
ovarian, testis, and prostate cancers. 
3.1   Estrogen receptors (ER) 
 The signaling pathways activated downstream of the 
estrogen receptors (ER) is critical for the development 
and growth of breast cancer. Classically, upon binding of 
the ligand 17 β -estradiol (E2) to ER, the dimerized recep-
tor gets translocated into the nucleus. Genomic action 
of ER is triggered by the binding of the dimerized ERs 
to the DNA directly in the estrogen response element or 
indirectly by tethering to other DNA-bound transcrip-
tion factors, leading to ER target activation. During this 
process, the E2-ER complex recruits functionally diverse 
coregulators such as SRC1, AIB1, MTA1, etc. to form mul-
tiprotein complexes, which will modulate ER function 
 [115] . In addition, ER can also exert nongenomic signaling 
through its interaction with cytosolic/membrane-asso-
ciated signaling proteins  [100] . Among the two ER tran-
scription factors (ER α and ER β ), ER α is overexpressed up 
to 70% in breast tumors compared to normal tissues  [100] . 
Both the genomic and nongenomic actions of ER α play a 
significant role in breast tumors because of their role in 
proliferation and metastasis  [116, 117] . In fact, bone and 
lung metastasis of tumor has been associated with their 
ER α expression levels  [118, 119] . On the other hand, ER β -
mediated signaling in breast tumor cells play a distinct 
role of antiproliferative  [120] and antimigratory function, 
and its expression level is inversely correlated with inva-
sive breast cancer  [121] . EMT is a key process that occurs 
during the invasion of tumor cells to the surrounding 
tissues, and ER can influence this process by interacting 
with the major regulators of EMT, the Snail and Slug  [122, 
123] . Collectively, deregulated genomic and nongenomic 
signaling through ERs and their coregulators underlie a 
majority of human breast cancers, which causes a huge 
percentage of cancer-related deaths in women. 
3.2   Androgen receptor (AR) 
 Androgen is a SH that stimulates growth, development, and 
maintenance of prostate cells by binding to the androgen 
receptor (AR), which is a member of the steroid-thyroid-
retinoid nuclear-receptor superfamily. Prostate cancer is one 
of the most common forms of cancer in men, and its develop-
ment and growth mainly depend on androgen in such a way 
that the ablation of androgen can suppress prostate tumor. 
However, overtime, they can develop into androgen-inde-
pendent prostate cancers (AIPC), which is a lethal form that 
progresses and metastasizes. Although, these are hormone-
refractory tumors, they still overexpress AR  [124] . Basically, 
androgens regulate the ratio of proliferating cells over the 
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dying cells by promoting proliferation and inhibiting apop-
tosis. Testosterone is the main circulating androgen, whose 
free form is converted into dihydrotestosterone (DHT) by the 
enzyme 5 α -reductase (SRD5A2) in the prostate. DHT is the 
most active hormonal ligand for AR, and upon its binding, 
AR homo-dimerizes and bind to the androgen response ele-
ments (AREs) in the promoter regions of its target genes. 
This AR homo-dimer complex will further recruit coregula-
tory proteins, which can be either coactivators or corepres-
sors depending on which the target genes will be activated 
or repressed  [125] . Most of the AIPCs still express AR but 
signal in a non-androgen-bound manner  [126] through their 
crosstalk with growth factor (GF) signaling pathways. GFs, 
such as IGF1, EGF, keratinocyte growth factor (KGF), and 
FGFs can activate AR in the absence of androgen  [127] . For 
instance, in mice, HER2 is overexpressed in AIPC condition, 
and it is shown to convert androgen-dependent cell lines 
into androgen-independent cells upon overexpression  [128] . 
HER2 might mediate this action through the antiapoptotic 
PI3K/Akt pathway activation  [129] . A crosstalk between AR 
and ERK has also been reported in prostate and molecular 
apocrine breast cancer, contributing to disease progression 
 [130 – 132] . 
4   Ancient signaling pathways 
in tumor 
 There are three important highly conserved signaling 
pathways that are hyperactive in the tumor cells. They are 
the multifunctional Hedgehog (Hh), Notch, and WNT sign-
aling, which regulate the basic cellular processes such as 
proliferation, differentiation and survival that underlie 
most of the critical cell fate decisions. 
4.1   Hedgehog (Hh) signaling 
 Hyperactive Hh signaling is an important hallmark of a 
large number of human cancers, including those of the 
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 Figure 1   RTK and SHR signaling. 
 The activity of growth factors such as EGF, FGF, IGF, PDGF, and VEGF family members are mediated by the RTK signaling. These receptors are 
made up of an extracellular region, a single transmembrane spanning region, and a cytoplasmic tyrosine kinase domain. The extracellular 
domain of the RTK binds to the respective GF ligands that cause receptor dimerization and subsequent autophosphorylation on multiple 
specific intracellular tyrosine residues, creating binding sites for specific proteins. Autophosphorylated RTKs stimulate small GTP-binding 
protein, Ras by recruiting SOS and its adapter protein GRB2 to the membrane. This initiates a series of signal transduction cascade. Ras 
activates PLC γ , which can also be activated by Src in a RTK-dependent or -independent manner through SHR. Activated PLC γ hydrolyses PIP2 
to release the second messengers 1,2-diacylglycerol (DAG) and IP3, in which DAG is the activator of PKC that activates Ras/Raf and thus 
ERK signaling, leading to the expression of transcription factors related to cell proliferation, migration, and angiogenesis. In addition, PKC 
also activates PLD that catalyzes the hydrolysis of PC to PA, activator of signaling cascades like mTOR. PA also inhibits PTEN, a tumor sup-
pressor that negatively regulate mTORC1 activity. IP3 activates Ca 2 +  release from the endoplasmic reticulum by binding to its intracellular 
receptor (IP3R). Thus, accumulated intracellular calcium displaces the inhibitory binding of caveolin to eNOS and induces NO production, 
which increases angiogenesis and vasopermeability. Another important intracellular pathway activated upon RTK signaling is the PI3K/Akt, 
which starts with the recruitment of PI3K (p85 α /p110 α ) to the receptor, enables p110 α to phosphorylate PIP2 and PIP3. Binding of PIP3 to 
Akt, allows Akt phosphorylation and partial activation by PDK1. Thus, partly activated Akt is fully activated by mTORC2. In turn, phospho-
rylated/fully activated Akt activates mTORC1 either directly or through its inhibitory action on TSC1/TSC2, which inhibits mTOR. mTORC1 
regulates S6K and HIF1 α , inducing translation of several genes including the ones participating in homeostatic responses to hypoxia. 
Although Akt signaling can promote cell proliferation, metabolism, migration, and angiogenesis, its important role is to function as an 
antiapoptotic signal by exerting its effect by phosphorylating a variety of downstream targets including mTOR, NF- κ B, eNOS, FOXO1, GSK3, 
etc. reviewed in  [95] . Here, the activities of FOXO1 and GSK3 are suppressed by p-Akt, reliving their inhibitory function on cell proliferation 
and survival. The activity of Akt is negatively regulated by PTEN, which inhibits phosphorylation of PIP2 to PIP3. Erk/MAPK is an important 
proliferative pathway, which is activated by Ras/Raf. Phosphorylated Erk dimer can function in the cytosol as well as in the nucleus where 
it activates many transcription factors related to cell proliferation. GFs may also activate ERK through PLC γ /PKC signals. The JNK pathway is 
a subgroup of MAP kinases that is phosphorylated/activated by MAP2K isoforms MKK4 and MKK7, which themselves are phosphorylated 
by MEKK1-4. Phosphorylated JNKs are translocated to the nucleus where it will activate its well-known target, c-Jun and other transcription 
factors, namely, activating transcription factor 2 (ATF2) and activator protein 1 (AP1). The JNK pathway can either have a pro-oncogenic role 
by promoting cell proliferation or can behave as a tumor suppressor by its proapoptotic effects or by employing tumor surveillance through 
the involvement of the immune system in a context-dependent manner (reviewed in  [96, 97] ). The JAK/STAT pathway also plays significant 
role in cell growth, survival, and differentiation. Activated RTK dimers allow phosphorylation of JAK proteins, which will activate STATs 
to form dimers. These dimers then get translocated into the nucleus and activate transcription of specific genes, related to survival and 
proliferation. Src is a nonreceptor cytoplasmic tyrosine kinase, which gets activated following RTK and/or integrins/FAK stimulation (FAK 
is a tyrosine kinase, which acts both as a signaling molecule and a scaffold protein). Src could induce activation of different transduction 
cascades including Ras/MAPK, PI3K/Akt, and STAT pathways  [98] and inhibit PTEN  [99] . Dysregulated steroid hormone (such as androgen, 
estrogen, and progesterone) signaling through their respective receptors results in uncontrolled proliferation and survival, leading to tumor 
initiation and progression. Ligand-induced receptor dimers bind either directly to specific DNA response elements or through other DNA-
bound transcription factors to alter the transcription of specific genes. Integration of steroid hormone (SH) and growth factor (GF) signaling 
occur through Erk/MAPK, Akt/PI3K, PKC, PLC, and STAT pathways (reviewed in  [100] ). 
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brain  [133] , skin  [134] , lung  [135] , prostate  [136] , gastro-
intestinal track  [137] , and pancreatic cancer  [138] . Hh 
is a morphogen that can act in a short- and long-range 
manner. There are three Hh proteins: Sonic Hh, Indian 
Hh, and Desert Hh, which transduce their signaling 
through glioma-associated (Gli) family of zinc finger tran-
scription factors (Gli1-3). Gli1 always functions as a strong 
transcriptional activator; Gli2 and Gli3 have both activator 
and repressor functions, although Gli2 mostly functions 
as an activator and Gli3 as a repressor. In the absence of 
Hh ligand, Gli1 is not transcribed, but Gli2 and Gli3 are 
expressed; however, they will be subjected to proteolytic 
cleavage to form the short repressor forms  [139] . Different 
ratios of Gli-activator (Gli-A) to Gli-repressor (Gli-R) have 
the potential to differentially regulate gene expression 
during embryo development  [140, 141] and tumorigenesis 
 [139] . This combination of Gli proteins is defined as the 
Gli code, and it is proposed to underlie specific cellular 
fates  [139, 142] . Patched (PTCH1-2) is the major receptor 
for Hh proteins, which normally inhibits the function of 
smoothened (SMO). Binding of Hh to the receptor releases 
PTCH-mediated inhibition on SMO allowing SMO to signal 
to downstream molecules. Hh signaling in vertebrates 
requires the presence of a nonmotile primary cilium 
where SMO is accumulated upon Hh signaling activation 
 [143] . Under tumorous conditions, hyperactivation of Hh 
pathway happens either by mutation of pathway com-
ponents, namely, PTCH, receptor and negative regulator; 
SMO, signaling mediator; or supressor of fused (SUFU), 
prevents nuclear translocation of Gli molecules and also 
inhibits Gli1-mediated transcriptional activity  [144] or by 
PTCH  [145] or SMO  [146] or Hh overexpression  [147 – 149] . 
Mutation of pathway components results in ligand-inde-
pendent constitutive pathway activation, and the latter 
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causes ligand-dependent pathway activation. When the 
tumor cell overexpresses the ligand, it can promote growth 
and survival of the neighboring tumor cell by signaling in 
an autocrine fashion. By this means, the tumor can be 
controlled by adding pathway inhibitors  [135] or can be 
accelerated by supplementing ligands  [137] . Alternatively, 
Hh-dependent signaling can also occur in a paracrine 
manner where the ligand produced by the epithelial cells 
signals to the underlying mesenchymal or stromal cells, 
which in turn signals back to regulate epithelial cell pro-
liferation and survival, by producing various signaling 
molecules. Apart from being activated in cancerous cells, 
hyperactive Gli code is the key factor of human glioma 
cancer stem cells  [133] . Stecca and Ruiz  [139] proposed 
that the naturally repressed form of Gli code is reverted 
when the tumor suppressors are lost upon mutations/epi-
genetic changes, resulting in uncontrolled proliferation 
of the cancer stem cells. Expression of the Hh pathway 
components has also been detected in human breast 
cancer stem cells  [150] , overall pointing to the possibility 
of therapeutic targeting of the stem cell population that 
ultimately cause tumor. Detailed reviews on Hh signaling 
can be found elsewhere  [139, 151] . 
4.2   Notch signaling 
 Notch is an evolutionarily conserved fundamental 
signaling pathway that regulates several events during 
embryo development and tissue homeostasis during 
adulthood through its four membrane-bound type I 
receptors (Notch 1 – 4) and five transmembrane ligands 
(Delta1, Delta3, Delta4, Jagged1, and Jagged2). Notch is a 
short-ranged signaling, and it requires cell-cell contact 
with each cell expressing either the receptor or the 
ligand. Signaling initiation occurs upon ligand-receptor 
interaction and the proteolytic cleavage of the notch 
intracellular domain (NICD) by a  γ -secretase complex 
whose key components are presenilin and nicastrin 
 [152] . Thus, liberated NICD gets translocated into the 
nucleus and binds to the DNA-binding transcriptional 
mediator protein, C-protein-binding factor 1 (CBF1)/
RBPjk  [153] , trading, therein, bound transcriptional 
corepressors with transcriptional coactivators, allow-
ing the transcription of the wide variety of Notch target 
genes. Mastermind-like transcriptional activator pro-
teins (MAML1-3) are shown to be required for Notch sign-
aling by forming a ternary complex with NICD and RBPjk 
 [154] . The members of mammalian Hairy/Enhancer of 
Split ( HES ) genes are generally considered as the effec-
tors of Notch signaling  [155] , but it also has other targets 
including the cell-cycle regulators, cyclinD1 and p21 
 [156, 157] . Apart from this canonical RBPjk-dependent 
Notch signaling, the noncanonical RBPjk-independent 
Notch signaling also exists, and it can also contribute to 
tumor formation  [158, 159] . 
 Arsenal of data from developmental and oncogenic 
studies suggests that Notch signaling can function in a 
context-dependent manner based on the cell type and 
stage of differentiation at which it is activated. During 
development and adult tissue homeostasis, Notch sign-
aling is mandatory to maintain neural, breast, hemat-
opoietic, and intestinal stem cells  [160 – 164] . Apparently, 
many tumors also possess pluripotent stem cell popu-
lation, which eventually generates large tumors  [165] , 
and Notch signaling actively takes part in controlling 
the fate of cancer stem cells from several tumors  [166] . 
In fact, emerging pieces of evidence suggest that Notch 
components are required for the survival of breast and 
intestinal cancer stem cells  [160, 162, 164, 167] . Notch 
signaling has been associated with a number of hemat-
opoietic and epithelial human tumors including colon, 
breast, lung, skin, cervical, prostate cancers, leukemia, 
and neuroblastoma  [167 – 170] . But, the way it works in 
tumor tissue is complex because in some cancers, it acts 
like a tumor suppressor and, in others, like an onco-
genic factor. For example, Notch2 functions as a tumor 
suppressor in breast cancer, while other Notch receptors 
are oncogenic  [171] ; however, in brain cancer, Notch2 
acts as an oncogene, whereas Notch1 has the opposite 
effect  [172] . 
 Notch signaling activation in invasive breast cancer 
cells is the result of the following one or more events: 
elevated levels of ligands, receptors, downstream targets, 
and downregulation of Numb, the inhibitor of Notch sign-
aling  [167, 173 – 175] . These changes lead to cell survival 
either by reduced apoptosis or increased cell proliferation 
through Akt/PI3K, ERK/MAPK, and c-Jun NH2-terminal 
kinase (JNK)/STAT pathways  [176] . Different Notch recep-
tors are upregulated in different cancers: high Notch1 
protein expression has been observed in human cervix, 
colon, lung, pancreas, skin, and brain cancers; Notch2 
mRNA and protein are overexpressed in human brain, 
cervix, colon, pancreas, and skin cancers; Notch3 and 
Notch4 proteins are overexpressed in human malignant 
melanoma and human pancreatic cancer; elevated Notch4 
mRNA expression has been reported in human breast 
cancer  [176] . Being a regulator of cell fate decision, Notch 
signaling is known to contribute to resistance against 
many cancer treatments  [167] . The following reviews can 
be referred for more information on Notch signaling in 
cancer  [167, 176] . 
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4.3   WNT signaling 
 WNT is another highly conserved pathway that is also fre-
quently deregulated in malignancies. Like Hh and Notch 
signaling, WNT signaling is also associated with stem cell 
homeostasis in many tissues, namely, intestine, colon, 
bone, blood, muscle, hair, and fat  [177 – 179] . This signaling 
pathway also mediates cell proliferation, migration, differ-
entiation, adhesion, and death  [180] . The term WNT is an 
amalgam of wingless from  Drosophila (Wg) and its mouse 
homolog int1. There are 19 WNT proteins in mammals. WNTs 
are soluble secreted factors that signal through its interac-
tion with cell surface G-protein-coupled receptors, Frizzled 
(FZD), and the coreceptors LRP5/6. WNTs activate at least 
three different signaling pathways: the canonical pathway 
that requires  β -catenin activation and WNT/Ca 2 +  and WNT/
planar cell polarity (PCP) noncanonical signaling pathways 
that are independent of  β -catenin  [181, 182] . In the canoni-
cal pathway, WNT-activated FZD will immediately recruit 
the cytosolic disheveled protein (Dvl1, 2, or 3) and regu-
late the intracellular concentration of  β -catenin by modu-
lating the activity of the  β -catenin destruction complex 
containing axis inhibitor (AXIN), adenomatous polyposis 
coli (APC), glycogen synthase kinase 3 (GSK3), and casein 
kinase 1 (CK1)  [183] . Mutations in  β -catenin and APC are 
reported in many human cancers  [184] , and the pathway is 
deregulated in colorectal and breast cancers  [181, 184 – 186] . 
Tumor cells either present an upregulation of WNT positive 
 Figure 2   Schematic representation of the ancient signaling pathways, Hh, Notch, and WNT. 
 Members of the Gli family of transcriptional factors are the effectors of Hh signaling. In the absence of Hh ligand (SHH, DHH, and IHH), Gli 
proteins are proteolytically cleaved into a lower molecular weight form (Gli-R), which acts as a transcriptional repressor, while the full-length 
Gli functions as an activator (Gli-A). Binding of Hh to its receptor, PTCH relieves its inhibition on SMO, allowing SMO-mediated accumulation 
of the full-length Gli-A form and its translocation into the nucleus where it activates Hh target genes. In the absence of Hh ligand, the SUFU 
interacts with Gli proteins, sequestering the Gli-A from in the cytoplasm, preventing their nuclear translocation and Hh signaling. Notch is 
a cell-cell communication pathway in which one cell expressing the plasma transmembrane ligand (Delta/Jagged) and the other expressing 
the receptor (Notch). Upon ligand binding, a series of proteolytic cleavage events occur, ultimately releasing the NICD into the cytoplasm and 
subsequent translocation into the nucleus. In the nucleus, NICD binds to RBPjk, a DNA-binding protein along with the transcriptional coac-
tivator MAML1 to recruit transcriptional coactivators (CoAs) in order to initiate transcription of Notch target genes. In the absence of NICD, 
RBPjk will be in association with corepressors (CoRs) that inhibits Notch target gene transcription. Activation of the WNT signaling cascade 
begins when the secreted WNT ligands bind to FZD receptor and LRP5/6 coreceptors resulting in downstream stabilization and nuclear trans-
location of the transcriptional coactivator  β -catenin through the activity of Dvl. In the nucleus, prior to WNT signaling, lymphoid-enhancing 
factor (LEF) and T-cell factor (TCF) are bound to the promoter/enhancer regions of WNT target genes, repressing their expression. Accumula-
tion of  β -catenin by WNT signaling leads to binding of  β -catenin to TCF/LEF, promoting transcriptional activation of several target genes. In 
the absence of WNT ligand,  β -catenin is associated with a cytoplasmic complex containing casein kinase 1 α (CK1 α ), GSK3, AXIN, and the APC 
protein. This complex promotes phosphorylation of  β -catenin and targets it for ubiquitination and subsequent degradation. 
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regulators or downregulation of negative regulators to acti-
vate the pathway. For instance, Dvl1 is upregulated  [187] , 
and a secreted WNT inhibitor, FZD-related protein 1 (FRP1) 
is downregulated/deleted in many breast cancers  [188] . 
Sustained expression of FRP1 in human breast cancer cell 
line dramatically impaired their ability to form tumor xeno-
grafts in mammary glands of nude mice  [189] . WNT recep-
tor FZD and coreceptors LRP5/6 are also overexpressed in 
many tumors. FZD1 overexpression in breast cancer cell 
line is reported to confer multidrug resistance through 
MRD1 induction  [190] . FZD7 expression in colon cancer cell 
lines has been accounted for canonical WNT pathway acti-
vation despite the presence of APC or  β -catenin encoding 
gene (CTNNB1) mutation  [191] . Likewise, LRP6 overexpres-
sion is defined as the characteristic of a subpopulation of 
breast cancer, and its silencing significantly reduced WNT 
signaling, suggesting LRP6 as a potential therapeutic target 
 [192] . Also, LRP5 expression is shown to be required for 
WNT-dependent mammary tumors  [193] . Perturbation of 
WNT signaling has been shown to inhibit proliferation and 
impair cell motility of human breast cancer cell lines  [185, 
186, 189] . Furthermore, during breast cancer metastasis, 
WNT signals are reported to promote EMT and migration 
through stabilization of Snail  [194] , which could be com-
promised by inhibiting WNT signaling  [195] . 
 The noncanonical pathways also play important roles 
in tumorigenesis  [196] . During the metastasis of melanoma, 
Wnt/Ca 2 +  pathway is involved in EMT through WNT5a  [197] . 
As PCP plays a crucial role in cell adhesion and movement, 
its dysfunction greatly correlates with tumor metastasis. 
WNT11- and WNT5a-activated WNT/PCP pathway  [198, 199] 
promote metastasis through Rac, Rho, and JNK in hepa-
tocellular carcinoma, melanoma, gastric, non-small-cell 
lung, colon, and breast cancers  [200, 201] . To add further 
complexity to the system, WNT5a is reported to function as 
an oncogene or tumor suppressor in a context-dependent 
manner, suggesting that PCP might be functioning as a 
tumor suppressor in the early stages of tumorigenesis and 
then in more progressed tumors as oncogene  [201] . Both 
the WNT/ β -catenin and noncanonical WNT signaling are 
also implemented in tumor angiogenesis  [202] . The fol-
lowing reviews are suggested for deeper understanding of 
WNT signaling in cancer  [183, 184, 201] . 
5   Other important molecules 
modulated during cancer 
 The multifunctional protein Src is an intracellular/
membrane-associated tyrosine kinase that regulates cell 
proliferation, angiogenesis, survival, differentiation, and 
cell movement by interacting with GF receptors, steroid 
hormone receptors (SHR), and many other adaptor pro-
teins. Through activation of different transduction cas-
cades including Ras/MAPK/ERK, PI3K/Akt, and STAT 
pathways, Src is capable of transforming normal cells 
into malignant ones (reviewed in  [203] ). Src also medi-
ates adhesion-dependent responses by functioning as an 
important mediator downstream of integrins  [204] . FAK is 
a tyrosine kinase, which can act as a signaling molecule 
or as a scaffold protein, enabling the recruitment of Src 
to integrin. Src-integrin interaction also functions syn-
ergistically with RTKs  [205] . In agreement,  β 1 integrin 
overexpression in non-small-cell lung cancer has been 
associated with its resistance to gefitinib, which targets 
the tyrosine kinase activity of EGFR  [206] . High c-Src activ-
ity is reported in several cancers, such as breast, colon, 
pancreatic, neural, ovarian, esophageal, gastric, lung, 
and melanoma  [207] . It is often co-expressed with GFs, like 
in the case of majority of breast cancers (over 70%) where 
it is co-overexpressed with HER family members  [100] . Src 
can phosphorylate and, thereby, inhibit the tumor-sup-
pressor protein PTEN  [99] . Src represents a viable target 
for antiangiogenesis therapy because it is reported to 
induce VEGF expression and angiogenesis in pancreatic 
cancer cells  [208] . In addition to augmenting GF signal-
ing, c-Src also mediates signaling through SHR, and it has 
been proposed to be important for E2-stimulated cellular 
proliferation through ER  [203, 209] . 
 Signal transducer and activator of transcription 
(STAT1-6) are second messengers of the JAK/STAT sign-
aling pathway in response to the binding of extracellu-
lar proteins, including GF, hormones, and cytokines and 
serves as the integrator of signaling pathways activated 
by GFs and hormones. Upon tyrosine kinase-mediated 
phosphorylation, STATs will homo- or heterodimerize and 
get translocated into the nucleus where it binds to STAT-
specific response elements on DNA to regulate transcrip-
tion of interferon-stimulated genes (ISGs). Dysregulated 
JAK/STAT signaling leads to tumor formation through 
increased angiogenesis, enhanced survival, and immuno-
suppression. Overexpression/activation of STAT3, STAT5a, 
and STAT5b has been described in many tumors including 
the lung, prostate, and breast cancers  [210 – 212] . 
 Phospholipase D (PLD) catalyzes the hydrolysis of 
phosphatidylcholine (PC) to produce phosphatidic acid 
(PA), the activator of signaling cascades. There are two 
PLDs identified in mammals (PLD, PLD2), which are acti-
vated downstream of WNT/ β -catenin signaling  [213, 214] . 
Polymorphisms or point mutations in PLD2 are found in 
colon and breast cancers, respectively  [215] . PLD-produced 
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PA, lies in the center of many key cell growth regulator 
pathways associated with cancer, namely, SOS/Ras  [216] , 
Raf/MAPK/ERK, and mammalian target of rapamycin 
(mTOR) pathways  [217, 218] . 
 The highly conserved phosphatidylinositol 3-kinase 
(PI3K) pathway regulates diverse cellular processes, 
including metabolism, angiogenesis, growth, survival, 
proliferation, apoptosis, and cell migration  [219] . Akt, the 
target of PI3K signaling, is activated upon phosphoryla-
tion by 3-phosphoinositidedependent kinase (PDK1) or 
mTORC2 or by other kinases  [220] . Several human cancers 
possess mutations in p110 α , the catalytic subunit of PI3K 
and PTEN at very high frequencies, resulting in increased 
activity of the PI3K/Akt signaling pathway  [221] . Phospho-
rylated-Akt can augment cancer in several ways: (1) Akt 
phosphorylates its substrate, FOXO (Forkhead box gene, 
group O; proapoptotic transcription factor) and enables 
its retention in the cytosol, causing increased cell prolif-
eration and survival  [222] . Inhibition of Akt signal causes 
FOXO nuclear translocation and subsequent activation of 
receptor gene expression  [223, 224] . (2) Akt can also influ-
ence eNOS and potentiate angiogenesis and vascular per-
meability  [88, 225] . (3) tuberous sclerosis complex 2 (TSC2) 
is also a substrate of Akt, which along with PTEN and LKB1 
are tumor suppressors that negatively regulate mTORC1 
activity  [221] . (4) Activated Akt inhibits GSK3 by phospho-
rylation, which might be mediating some of the antiapo-
ptotic effects of Akt  [226, 227] ; (5) PI3K/Akt pathway can 
enhance NF- κ B-dependent transcription, which regulates 
cell fate decisions, such as apoptosis and proliferation 
 [228] . (6) PI3K/Akt pathway activation can also confer cell 
survival signal by suppressing apoptosis, such as the case 
with anoikis, apoptosis induced by inadequate or inap-
propriate cell-matrix interactions  [229] . 
 Phosphorylation of TSC2 by Akt relieves its negative 
regulatory effect on mTOR, making it as a primary effec-
tor of Akt signaling  [230] . mTORC1 activation causes phos-
phorylation of its effector ribosomal protein S6 kinase 
1 (S6K1), which further phosphorylates the ribosomal 
protein S6 that allows translation of mRNAs encoding 
different proteins  [231] . mTORC1 also regulates VEGF by 
phosphorylating hypoxia-inducible factor  α (HIF-1 α ) 
leading to its accumulation in tumor cells  [232] . HIF-1 α 
is predominantly responsible for the adaptation of solid 
tumors to hypoxia by mediating angiogenesis and anaero-
bic metabolism  [233] . 
 Tissue factor (TF)/ protease-activated receptor (PAR)-
mediated signaling shapes the tumor microenvironment 
by inducing several cytokines, chemokines, and GFs in 
addition to their involvement in tumor cell migration 
 [234, 235] . 
 There are also other factors that influence tumor 
development and progression. Homologous recombina-
tion (HR) is a fundamental cellular process, which upon 
dysfunction could cause genomic instability leading to 
malignancies. Mutations in HR regulators, BRCA1and 
BRCA2, are also reported to cause hereditary breast and 
ovarian cancers  [236] . Similarly, mutation in another 
HR regulator, RAD51C is also associated with breast and 
ovarian cancer  [237] , implying a crucial role for HR and its 
regulatory genes in cancer prevention. 
6   The tumor microenvironment 
 The tumor microenvironment could be defined as the 
supportive environment existing around the tumor that 
facilitates growth, survival, and invasion of tumor cells by 
providing appropriate signaling molecules, chemokines, 
soluble factors, and extracellular matrix. These cues 
come from the surrounding stromal cells, which include 
endothelial cells, necessary for tumor angiogenesis; fibro-
blasts that produce chemokines and involved in extracel-
lular matrix remodeling; and inflammatory cells. Owing to 
the dynamics in stromal cells, metabolic alterations, and 
modulations in the extracellular matrix, the tumor micro-
environment is under constant evolution. The network 
between the tumor and the nearby stromal cells are very 
crucial to establish tumors. Moreover, the tumor micro-
environment is also known to regulate the behavior of 
cancer stem cells  [1, 238] . The tumor microenvironment 
is influenced by crosstalks between the aforementioned 
signaling pathways. 
 Target genes of SHH/Gli signaling can also directly 
or indirectly lead to the synthesis of signaling molecules, 
some of which may enrich the tumor microenvironment 
facilitating tumor growth and progression  [239 – 241] . Hh 
signaling can be modulated by GFs like EGF  [242] . In epi-
dermal cells, EGFR-mediated Raf/MEK/ERK intracellular 
pathways cooperate with Gli1/2 proteins to regulate the 
Notch ligand,  jagged2 transcription, linking GF, Hh, and 
Notch signaling  [243] . Schreck et al.  [244] showed that the 
effector of Notch signaling, Hes1, can directly bind to Gli1 
promoter and repress its transcription causing low Hh 
activity in glioblastomas and suggested that targeting both 
pathways simultaneously may be more effective in the 
elimination of glioblastoma cells. Jagged1 downregulation 
was also accounted for reduced  gli2 expression in ovarian 
cancer cells in a Notch-independent fashion. Interest-
ingly, this relationship between Jagged1 and Gli2 worked 
both ways as knockdown of Gli2 diminished  jagged1 
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expression level  [245] . Furthermore,  jagged1 expression 
has been considered as a potential link between Notch 
and WNT signaling pathways in ovarian  [246] and colo-
rectal  [247] cancers. Gli ’ s can also be modulated by other 
signaling pathways: TGF- β /SMAD3 pathway in associa-
tion with WNT/ β -catenin signaling can directly transcribe 
Gli2, which upregulates Hh target genes including  gli1 
expression in an Hh-independent manner  [242, 248] . 
Notch, being a cell-cell communication signaling, can 
occur between tumor cells and stromal cells  [249, 250] , 
promoting angiogenesis  [251] . For instance, the Notch 
ligand,  jagged1 , is expressed both in the stromal (endothe-
lial cells) and the tumor compartments of ovarian cancer 
and serves as a putative target for therapies. Selectively 
targeting Jagged1 in the tumor stroma significantly 
reduced microvessel density, and its combined inhibition 
in stromal as well as ovarian tumor cells greatly reduced 
the overall tumor size  [245] , suggesting the role of Jagged1 
in angiogenesis and cell proliferation. WNT signaling 
from the stromal cells also has its role to play in tumor 
progression (colorectal cancer:  [252] ), differentiation, 
and migration of the tumor cells  [253] . Recently, Notch2 
was identified as the target of WNT/ β -catenin signaling 
in colorectal cancer cells  [254] . But another study in colo-
rectal cancer uncovered an unexpected suppressive role 
of Notch1 on WNT/ β -catenin target genes  [255] . Owing to 
such strong interactions between the ancient Notch, WNT, 
and Hh signaling pathways, recent studies suggest that 
inhibiting these pathways in combination with traditional 
chemotherapies may provide enhanced chemosensitivity 
 [183, 256, 257] . 
 GF constitute an important mode of communication 
between the tumor epithelium and stromal components 
 [258] . PDGF, released by the tumor cells, signals through 
the stromal cell-expressed receptors, and in turn, they 
receive growth inductive signals from the stromal cell-
secreted IGF1  [38] . The stromal cell-derived chemokine 
SDF1and its receptor CXCR4-mediated signaling play 
influential role in the metastasis of ER α -positive invasive 
breast cancers  [259, 260] . In addition, GF can also contrib-
ute to the aberrant growth of tumor stem cells as it has 
been recently illustrated for glioblastoma-derived stem-
like cells  [238] . The influence of various factors on tumor 
microenvironment has been reviewed in the following 
articles: SHH:  [240] , Notch:  [251, 261] , WNT:  [262] . 
 The tumor microenvironment being a birthplace for 
the activation of various signaling pathways provides the 
perfect environment for dormant metastases to flourish. 
Metastasis is a deadly process in malignancies that con-
tributes to the majority of cancer-related deaths. In order 
to metastasize, the tumor cell should separate itself from 
the primary tumor, navigate the stromal tumor microenvi-
ronment through vasculature and/or lymphatic channels, 
and invade to a new location to establish the microme-
tastasis at a distant site  [263] . EMT is a crucial step in 
this process, which is a result of convergent activation of 
several transcription factors (Snail, Slug, Twist, ZEB1/2, 
and SMADs) by multiple signaling pathways, namely, 
TGF- β , WNT, Notch, and Hh  [264] . Often, the increas-
ingly complex tumor microenvironment also accounts for 
therapeutic resistance. The stromal tissue-derived CXCR4 
signaling is sufficient to drive metastasis of ER α -positive 
breast cancers and foster endocrine therapy resistant via 
increased MAPK signaling  [260] . Mostly, drug resistance is 
associated with MAPK, PI3K/Akt, and PKC γ pathway acti-
vation. Owing to these reasons, combination of therapies 
targeting different factors are beneficial than targeting 
a single tumor inducer. This is the case in the treatment 
of breast cancer, where both ER and HER2 are targeted. 
These discussions suggest that it is necessary to carefully 
analyze the tumor microenvironment to provide proper 
treatment. 
7   Functionalization of nanoparticles 
for cancer therapy 
 Nanoparticles are submicron-size carrier systems com-
posed of natural or synthetic polymers with the size 
range of 10 – 1000 nm in which the drug may be dissolved, 
entrapped, encapsulated, or attached. Nanoparticle-
mediated early diagnostic methods and targeted thera-
pies serve as a potential tool to fight cancer because of 
their ability to achieve site-specific action of the drug at 
therapeutically optimal rate and dose while reducing the 
unwanted toxic side effects  [265] . In order to achieve these 
qualities, the nanoparticles are designed considering 
several parameters as discussed below. 
7.1   Challenges in nanodrug delivery 
and strategies to overcome them 
 The physiology of every human organ is designed to 
perform their respective functions at optimum levels and 
to prevent the invasion of toxins, antigens, and pathogens. 
These protective functions are executed by physical and 
biochemical barriers, which are also responsible for ham-
pering drug delivery to the targeted site. The physical bar-
riers include the cell membranes, tight junctions between 
adjacent epithelial cells, extracellular matrix, mucus 
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layer, etc., while the biochemical barrier comprises of the 
efflux pumps, catabolic enzymes that leads to drug metab-
olism/detoxification, drug sequestering to acidic com-
partments, and drug deactivation mechanisms  [266] . As a 
result, only a small percentage of drugs will finally reach 
the targeted cells. This limited delivery is not only true for 
the conventional cancer drugs but also for gene therapy, 
which stands as an attractive therapeutic approach for 
cancer. In gene therapy, functional DNA molecules or 
small interfering RNA (siRNA) are effectively delivered 
into malfunctioning cells to replace the missing/mutated 
gene or to induce posttranscriptional gene silencing, 
respectively  [267] . Intravenously injected DNA-containing 
nanoparticles must be able to successfully circulate in the 
bloodstream by avoiding serum proteins that may bind to 
the particles and increase their size, paving the way to be 
eliminated by Kupffer cells present in the reticuloendothe-
lial system. Subsequently, the circulating nanoparticles 
should extravasate into the tumor tissue and contact the 
cell surface by crossing the physical/extracellular bar-
riers (cell membranes, tight junctions, and extracellular 
matrix). Once internalized by the cell, the DNA within the 
nanoparticle must escape the biochemical and intracel-
lular barriers (lysosomal degradation, endocytic vesicles, 
degradation by cytosolic nucleases) and find its way into 
the nucleus and target the transcription active regions. 
 Another prominent barrier is the blood-brain barrier 
(BBB), which continues to be a challenge in the treatment 
of brain cancer  [268] . The brain, being the central organ 
of the human body, have capillaries that have evolved as 
a natural defense mechanism by restricting the move-
ment of molecules between blood and brain. Successful 
passage of molecules across the BBB is constrained by 
tight junctions between capillary endothelial cells, efflux 
transport proteins expressed in the luminal (blood) side 
of the BBB, and degrading enzymes present in the cyto-
plasm of endothelial cells. However, small molecules with 
appropriate lipophilicity, molecular weight, and charge 
can pass through the BBB. This action is facilitated by 
transporters expressed at the luminal and basolateral 
(brain) side of the endothelial cells, specific receptors 
expressed on the luminal side of the endothelial cells, and 
by passive diffusion. Among the several strategies applied 
to bypass BBB, employing nanoparticles functionalized 
based on the native receptors or transporters localized 
in the luminal (blood) side of the endothelial cells have 
been promising, to date, in brain cancer therapies  [268 –
 270] . The intravenously injected nanoparticles are mostly 
transported across the BBB by endocytosis, which will 
then undergo transcytosis. Usually, polyethylene glycol 
added (PEGylated), surfactant coated (PS 80), targeting 
molecule attached biodegradable and nonbiodegrada-
ble nanoparticles have been used in  in vitro and  in vivo 
brain-targeting studies  [270] . Biologically active polymer 
core/shell nanoparticles self-assembled from TAT-PEG-b-
cholesterol (TAT-PEG-b-Chol) were synthesized and suc-
cessfully used to deliver ciprofloxacin antibiotic across 
the BBB  [271] . Polyethylene glycol conjugated (PEGylated) 
gold nanoparticles functionalized with EGF was used to 
selectively deliver therapeutic drug, phthalocyanine 4 (Pc 
4) to brain glioma tumors for PDT  [272] . Recent develop-
ment in the field of drug delivery to the central nervous 
system has been thoroughly discussed in the follow-
ing reviews  [268, 270] . Thus, to increase the therapeutic 
efficacy of nanoparticles, they must be targeted to the 
required site through appropriate approaches. 
7.2   Passive and active targeting 
of nanoparticles 
 In order to create nanoparticles that exclusively target 
tumor cells, two basic strategies are employed: passive and 
active targeting methods  [273] . In passive targeting, the 
pathophysiologic features of cancer tissue are exploited 
for the accumulation of nanoparticles in tumor sites. 
One such important parameter is the newly formed leaky 
blood vessels that supply nutrients and oxygen to tumors 
exceeding 2 mm 3 in size  [274] . In addition, tumor cells also 
present higher compound retention time than healthy 
cells, which allow the retention of nanoparticles in tumor 
cells for a prolonged period of time  [275] . Together, these 
parameters provide an enhanced permeability and reten-
tion (EPR) effect, the major determinant of passive target-
ing. This way of delivering nanoparticles is reported to be 
an apt strategy for gene therapy. Considering the endoso-
mal/nuclease degradation and the negative charge of DNA 
molecules, it is a challenging task to deliver the DNA or 
RNA to the target cells, make them to cross cell membrane 
and enter the nucleus. Although, virus-mediated DNA 
delivery is widely used to achieve high expression rates, 
they have the limitations of being toxic, immunogenic, 
and expensive. Alternatively, biodegradable, functional-
ized polymeric nanoparticles are utilized in therapy to 
meet this requirement. Owing to safety, sustained release 
capacity, and the ability to rapidly escape the endolyso-
somal pathway, poly-(lactic-co-glycolic acid) (PLGA) 
nanoparticles have been suggested as a good gene deliv-
ery system  [276] . Accordingly, pigment epithelial-derived 
factor (PEDF) gene-loaded PLGA nanoparticles have been 
demonstrated to be an innovative therapy for colon car-
cinoma by inducing apoptosis, decreasing microvessel 
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density, and inhibiting angiogenesis  [277] . Modifying the 
surface of the gene carriers with hydrophilic, flexible, non-
ionic polymers like PEG and conjugating targeting moie-
ties are efficient strategies to improve circulation time and 
site-specific delivery, respectively. However, PEGylation 
can invariably compromise the specificity of nanoparti-
cles  [278] . So, it is vital to balance between the specificity 
of nanoparticles and their delivery efficiency to achieve 
optimal results. Passively endocytosed logic gate nano-
particles, developed with a dual pH-responsive random 
copolymer (poly- β -aminoester ketal-2), has been vali-
dated as a novel gene delivery system by Morachis et al. 
 [279] . These nanoparticles possess the ability to remain 
hydrophobic at physiological pH (pH 7.4) but undergo a 
switch from hydrophobic to hydrophilic at low endosomal 
pH, triggering their rapid fragmentation followed by con-
comitant release of the encapsulated DNA. However, inad-
equate EPR effect due to variations in the permeability of 
tumor blood vessels is a limiting step in achieving optimal 
nano drug delivery through passive method. Active target-
ing method could be applied to overcome this limitation. 
 In active targeting method, the nanoparticles are 
attached to specific moieties, namely, antibodies, pep-
tides, or other small molecules to increase their specific-
ity to the target site. Surface-functionalized nanoparticles 
developed by impregnating tumor-specific ligands or 
novel tumor biomarkers on the surface of the nanopar-
ticles significantly improve their targeting efficiency. 
Enhanced  in vitro cellular toxicity has been achieved by 
docetaxel-encapsulated PLGA-b-PEG nanoparticle surface 
functionalized with the A 10 2 ′ -fluoropyrimidine RNA 
aptamer that recognizes the prostate-specific membrane 
antigen (PSMA) ’ s extracellular domain is a good example 
for the utilization of biomarkers as targeting moiety  [280] . 
However, it should be noted that most of the biomark-
ers highly expressed in tumor cells are also expressed 
in healthy cells at comparatively lower levels. For this 
reason, it is crucial to choose receptors that are overex-
pressed between 10 4 and 10 5 copies/cell in the tumor cells 
than in the normal cells  [281] . Nowadays, monoclonal 
antibody-conjugated nanoparticle-mediated delivery of 
antineoplastic agents has achieved extraordinary poten-
tial in cancer therapy  [282] . For instance, docetaxel con-
taining PEGylated chitosan nanocapsules conjugated 
to a monoclonal antibody against the transmembrane 
tumor-suppressor protein TMEFF-2 presented a delayed 
and prolonged action on non-small-cell lung carci-
noma mouse xenografts compared to the free drug  [283] . 
Although circumventing multiple drug resistance (MDR) 
is an advantage of using active over the passive targeting 
strategy  [284] , multifunctional nanoparticles can have 
nonspecific interactions with healthy cells, triggering 
immunogenicity and subsequent nanoparticle clearance 
 [278] . However, many new formulations are developed to 
match the requirement of the disease and the body, with 
diagnostic and therapeutic applications. Recently, a new 
formulation combining the properties of liposomes and 
nanoporous particles called  “ protocells ” were developed 
to treat human hepatocellular carcinoma  [285] . These pro-
tocells exhibited 10,000-fold greater affinity toward carci-
noma cells than the healthy hepatocytes, endothelial, or 
immune cells and displayed ameliorated capacity, stabil-
ity, specificity, and controlled release of multicomponent 
cargos at high concentrations within the cytosol of cancer 
cells  [285] . 
 Most of the ligand-receptor interactions mentioned 
in the first section of this review functions as a putative 
route for interaction and internalization of drug-loaded 
nanoparticles by endocytosis ( Figure 3 ). Here, we brief 
some examples on the utilization of these signaling 
pathways/molecules for nanoformulation-mediated tar-
geted drug delivery, and many other formulations are 
provided in  Table 1 . A chimeric protein, GFP-FRATtide-
conjugated silica nanoparticles were designed to target 
WNT signaling pathway. FRATtide is an inhibitor of GSK3, 
and its delivery to the human embryonic kidney cells 
and rat neural stem cells greatly affected WNT signaling 
cascade by increasing  β -catenin levels and transcription 
of WNT target genes, such as  c-Myc  [307] . Functionalized 
nanoparticles have also been employed to target tumor 
angiogenesis as a means to reduce tumor growth. Ruthe-
nium-modified selenium nanoparticles (Ru-SeNPs) have 
been shown as potential antiangiogenic agents in human 
umbilical vascular endothelial cells through inhibition of 
FGFR1 and its downstream ERK and Akt pathways  [299] . 
Even SHRs can be targeted by functionalized nanoparti-
cles. ER- α located on the cell membrane  [315] was targeted 
by thiol-PEGylated tamoxifen derivative plasmonic gold 
nanoparticles, which exhibited 2.7-fold enhanced drug 
potency compared to the free drug in ER-positive breast 
cancer cells  [302] . RTK also facilitates effective nano drug 
delivery. Rapamycin-loaded PLGA nanoparticle surface 
conjugated with EGFR-antibodies presented superior anti-
proliferative activity over unconjugated nanoparticles and 
native rapamycin, due to higher cellular uptake on malig-
nant breast cancer cells overexpressing EGFRs  [228] . Pacli-
taxel was actively targeted to EGFR-overexpressing cancer 
cells by utilizing chimeric anti-EGFR monoclonal anti-
body cetuximab surface-conjugated O-carboxymethyl chi-
tosan nanoparticles reported to enhance cell death  [294] . 
c-Src can effectively activate EGFR, and it was recently tar-
geted by c-Src antisense oligonucleotide complexed with 
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PAMAM denderimes. This formulation reduced c-Src and 
EGFR-dependent target gene expression in human colon 
cancer cells  [316] . 
7.3   Nanoparticles in photodynamic 
therapy (PDT) 
 In addition to the aforementioned applications, nano-
particles can also function as photosensitizer carriers 
in photodynamic therapy (PDT). PDT is an established 
cancer therapy particularly for superficial tumors, where 
the previously administered photosensitizer, accumu-
lated in the tumor site, will be excited by nonthermal light 
(635 – 760  nm) irradiation. Thus, excited photosensitizer 
along with molecular oxygen generates singlet oxygen 
( 1 O 2 ), which mediates PDT-induced cell death. Thus, the 
efficiency of PDT is determined by the successful for-
mation of  1 O 2 (2). For this purpose, both biodegradable 
and nonbiodegradable nanoparticles are useful. When 
biodegradable nanoparticles are used, the photosensitizer 
released by the particle will be excited to produce  1 O 2 . But 
the photosensitizer will remain inside the nonbiodegrada-
ble nanoparticle, which allows efficient  1 O 2 diffusion  [317] . 
Owing to its several advantages over other polymers used 
in PDT  [276] , Gomes et al. used PLGA-loaded bacteriochlo-
rophyll-a (BChl-a) photosensitizer and obtained almost 
complete phagocytosis after just 2  h of incubation with 
macrophage cells  [318, 319] . PLGA has also been utilized to 
load hydrophobic photosensitizer molecule zinc phthalo-
cyanine (ZnPc) and illustrated to exhibit tumor regres-
sion in tumor-bearing mice, compared to free ZnPc  [320] . 
However, polylactic acid (PLA) nanoparticles performed 
better than PLGA particles when the hydrophobic natural 
photosensitizing compound (Hypericin, Hy) from  Hyperi-
cum perforatum was applied in ovarian cancer cells  [321] . 
The nondegradable nanoparticles used in PDT are mostly 
ceramic-based (example: organically modified silica or 
organically modified silicate  – ORMOSIL  [322] ) or metallic-
based (example: gold  [323] ) or made from polyacrylamide 
A B
 Figure 3   Schematic representation of active (A) and passive (B) targeting. (A) In the active targeting method, the nanoparticles conjugated 
with specific moieties such as antibodies, peptides, or other small molecules targeting various cell surface receptors are internalized into 
the cell through receptor-mediated endocytosis. The acidic nature of the endosomes will destabilize its membrane resulting in the release 
of different components of the internalized nanoparticle as well as the entrapped drug into the cytosol of the cell. (B) Formation of blood 
vessels is crucial to supply nutrients and oxygen to solid tumors. Thus, newly formed blood vessels possess several gaps in between the 
endothelial cells making a leaky vasculature. In the passive targeting strategy, the nanoparticles take advantage of these leaky blood 
vessels to reach the tumor. Moreover, the absence of a well-defined lymphatic system in tumor tissue also improves the compound reten-
tion time. These properties of the tumor cells together make the ERP effect that facilitate the accumulation of nanoparticles and therein-
entrapped drug at higher concentration in the tumor site. 
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 Table 1   Comprehension of nanoparticle-based approaches to target the aforementioned signaling pathways/molecules. 
Nanoparticles   Functional molecule   Reason for functalization   Target   References 
Glutaraldehyde cross-linked albumin 
nanoparticles
  Single variable domain of a 
EGFR antibody (Ega1)
  EGFR-positive 14C squamous 
head and neck cancer cells
  EGFR    [286] 
Gold nanospheres and nanorods   IgG antibody   Oral cancer   EGFR, HERI, 
ErbB1
   [287, 288] 
PLGA-PEG-PCL nanoparticles   EGFR peptide   MDR in breast and ovarian 
cancer
  EGFR    [289] 
Poly (ethylene glycol)-poly( ε -
caprolactone) block copolymer micelles
  GE11 peptide   Active targeting of EGFR-
overexpressing cancer cells
  EGFR    [290] 
Lipid-based nanoparticles   Nickel   Epidermoid carcinoma cells 
A431
  EGFR    [291] 
Rapamycin-loaded PLGA nanoparticles   EGFR antibody   Breast cancer   EGFR    [292] 
Catanionic solid lipid nanoparticles   EGFR antibody   Human brain malignant 
glioblastomas cells (U87MG)
  EGFR    [293] 
PTXL loaded O-carboxymethyl chitosan 
nanoparticles
  Cetuximab monoclonal 
antibody
  Lung cancer   EGFR    [294] 
pH-sensitive immunoliposomes   EGFR antibody   Lung cancer   EGFR    [295] 
PEG-PCL-cetuximab-immunomicelles   Anti-EGFR monoclonal 
antibody.
  EGFR-overexpressing tumor 
cells
  EGFR    [296] 
Gold nanoparticles   Highly stable FGF1 variant   FGFR-overexpressing cancers  FGFRs    [297] 
Cisplatin-loaded gelatin nanoparticles   Heparin   Breast cancer   FGFR2    [298] 
Selinum nanoparticles   Ruthinum (11) polypyridyl   Liver cancer   FGFR1, ErK, Akt    [299] 
Gold nanoparticle   VEGF antibody   Kill B-chronic lymphocytic 
leukemia cells
  VEGF pathway    [300] 
Doxirubicin-loaded liposomes   Estrogen   Breast and uterus cancers   ER    [301] 
Plasmonic gold nanoparticles   Thiol-PEGylated tamoxifen 
derivative
  Breast cancer   ER    [302] 
Lipid nanoparticles   AR- si RNA   Prostate cancer   AR    [303] 
PLGA conjugated with PEG 
nanoparticles
  HPI-1 (Gli1antagonist)   Medulloblastomas, 
hepatocellular carcinoma
  Hh signaling    [304, 305] 
PLGA nanoparticles   DCAMKL-1-specific siRNA   Colon cancer   Notch signaling    [306] 
Silica nanoparticles   FRATtide peptide   HEK 293 cells   WNT signaling    [307] 
LY294002-encapsulated PLGA 
nanoparticle
   –   Inhibition of PI3K-mediated 
angiogenesis in melonama 
cells
  PI3K pathway    [308] 
Liposome-polycation-hyaluronic acid 
(LPH) nanoparticle
  GC4 single-chain variable 
fragment (scFv) tumor-targeting 
human monoclonal antibody
  c-Myc, MDM2, and VEGF-
siRNA and miRNA to lung 
metastasis murine model
  MAPK signaling    [309] 
PEG-coated core-cross-linked polymeric 
micelles
  EphB4-binding peptide TNYL-
FSPNGPIARAW and labeled with 
Cy7 and indium 111
  Fluorescence imaging of 
EphB4 in prostate cancer 
cells
  EphB4    [310] 
Magnetic iron oxide nanoparticle   PTEN gene expression plasmid   PTEN gene delivery for to 
reverse cisplatin resistance 
in lung cancer
  PTEN gene 
delivery
   [311] 
Polyamidoamin polymers, PAMAM 
nanoparticals
  Antisense oligo c-Src   Knocking-down c-Src in 
colon carcinoma cell line
  c-Src pathway    [239] 
Large unilamellar vesicle (LUV) 
nanoparticle
  PEGylated particle containing 
the Jak3 tyrosine kinase 
inhibitor, WHI-P131
  Leukemias with constitutive 
Jak3-STAT3/STAT5 activation
  Jak3/STAT 
pathway
   [312] 
PEGylated chitosan (CS) nanocapsules   Monoclonal antibody anti-
TMEFF-2
  To treat non-small-cell lung 
carcinoma
  TMEFF-2    [283] 
Liposomes   Mitochondrial-targeting 
molecule-Dequalinium 
polyethylene glycol-distearo
ylphosphatidylethanolamine 
conjugate
  To treat non-small-cell lung 
carcinoma
  To enhance 
cytotoxic effect 
in mitochondria
   [313] 
Star-shaped PLGA-vitamin E TPGS 
copolymer nanoparticles 
  Cholic acid   To treat cervical cancer   For better 
biocompatibility, 
   [314] 
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polymers  [324] . Moreover, nonbiodegradable nanoparti-
cles have the potential to perform multiple functions in 
combination with PDT  [317, 325] . A polyacrylamide multi-
functional platform with a contrast enhancer for magnetic 
resonance imaging (MRI), photosensitizer (Photofrin1) 
for PDT, PEG surface coating and targeting moiety (the 
integrin-targeting RGD peptide) was synthesized, and 
each functionalization aspect was demonstrated to be suc-
cessful by Kopelman et  al.  [326] . Hybrid gold-iron oxide 
nanoparticles  [327] and lanthanide-doped upconversion 
nanoparticles  [328] are among the many other new formu-
lations that possess diagnostic and PDT tools. 
8   Conclusions 
 Signaling interactions enriching the tumor microenvi-
ronment and altered signaling molecules in tumor cells 
provide potential strategies for targeted nano drug deliv-
ery. Over the past years, substantial effort has been made 
toward the development and advancement of multifunc-
tional nanoparticles for cancer diagnosis and therapeutic 
purposes. As it has been discussed above, functionali-
zation of nanocarriers by modifying their surfaces with 
various targeting moieties, namely, antibodies, peptides, 
and other small molecules, has significantly improved 
their targeting as well as delivery efficiency. Antibody-
conjugated nanoparticles seem as a straightforward way 
to achieve receptor-mediated endocytosis of the particle at 
the disease site. In addition to being a route for entry, it is 
also possible to activate an array of intracellular pathways 
leading to cell death or proliferation or angiogenesis, etc., 
when the receptors are targeted. Furthermore, there are 
many upcoming multifunctional nanoformulations such 
as magnetic nanoparticles, which through their real-time 
monitoring ability look promising for clinical use in the 
area of disease diagnosis and drug delivery to cancer cells 
 [329] . Emerging data suggest that it is possible to simul-
taneously target two important pathways to improve the 
treatment efficiency. A bispecific antibody, anti-PDGFR-
B/VEGF-A, capable of attenuating angiogenesis through 
two distinct pathways was reported by Mabry et al.  [330] , 
and it is yet to be applied for nano delivery method, which 
could further improve the efficacy. As cancer is a disease 
of dysregulated signaling pathways, there are much more 
to explore at the level of basic research, and also, there is 
a huge possibility to adapt the known knowledge for the 
nano applications. Although, biomarkers expressed on 
tumor cells could be used to design personalized nanopar-
ticles to treat cancer, it is important to optimize the parti-
cles to have balanced targeting and delivery competence 
because overloading the carriers with targeting moieties 
can trigger immunogenicity and subsequent clearance at 
the same time. However, knowledge accumulated from 
years of research has enabled many nanoparticle-based 
drugs to be approved or to be tested in the clinic  [273] . It 
is time to acknowledge that the nanoparticle approach is 
a wiser way to fight cancer in a robust and personalized 
manner with minimal side effects. 
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